Immunotherapy with monoclonal antibodies (mAbs) that block PD-1-dependent negative regulation of the immune response has been a major success story in the treatment of melanoma [1–5] and other malignancies, such as lung cancer [6] and Hodgkin’s disease [7]. The gene discussed is PDCD1; the disease is melanoma.